The Pro115Gln and Pro12Ala PPAR gamma gene mutations in obesity and type 2 diabetes

被引:116
作者
Clement, K
Hereberg, S
Passinge, B
Galan, P
Varroud-Vial, M
Shuldiner, AR
Beamer, BA
Charpentier, G
Guy-Grand, B
Froguel, P
Vaisse, C
机构
[1] Hop Hotel Dieu, Lab Nutr, F-75004 Paris, France
[2] Hop Hotel Dieu, Med Serv, F-75004 Paris, France
[3] Inst Biol Lille, CNRS, UPRESA 8090, F-59000 Lille, France
[4] CNAM, ISNTA, F-75004 Paris, France
[5] Ctr Hosp Sud Francilien, Serv Diabetol, F-91108 Corbeil Essonnes, France
[6] Univ Maryland, Div Endocrinol Diabet & Nutr, Baltimore, MD 21201 USA
[7] Johns Hopkins Univ, Baltimore, MD USA
关键词
obesity; PPAR gamma; diabetes; association study;
D O I
10.1038/sj.ijo.0801191
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE: Peroxisome-proliferator-activated receptors gamma (PPAR gamma), is a key regulator of adipocyte differentiation and energy balance. Two naturally occurring mutations in the PPAR gamma gene, Pro115Gln and Pro12Ala, have recently been shown to impair the function of the PPAR gamma 2 isoform of the receptor and to be associated with obesity or diabetes-related phenotypes in different populations, SUBJECTS: We studied the occurrence and possible associations of the Pro115Gln and Pro12Ala in the PPAR gamma 2 gene with several clinical and metabolic phenotypes in three independent targe populations of non-obese non-diabetic, type 2 diabetic, and morbidly obese French Caucasians. RESULTS: The Pro115Gln mutation was not found in any of the 1069 subjects screened including 626 obese patients, The frequency of the Pro12Ala mutation was similar in all groups (0.08, 0.11, 0.09) and was not associated with BMI or any of the clinical parameters tested. CONCLUSIONS: We conclude that the Pro115Gln mutation is not a frequent cause of morbid obesity in Caucasians and that the Pro12Ala mutation is not associated with clinically significant changes in these populations.
引用
收藏
页码:391 / 393
页数:3
相关论文
共 18 条
  • [1] Association of the Pro12Ala variant in the peroxisome proliferator-activated receptor-γ2 gene with obesity in two Caucasian populations
    Beamer, BA
    Yen, CJ
    Andersen, BE
    Muller, D
    Elahi, D
    Cheskin, LJ
    Andres, R
    Roth, J
    Shuldiner, AR
    [J]. DIABETES, 1998, 47 (11) : 1806 - 1808
  • [2] Insulin resistance: Current concepts
    Bloomgarden, ZT
    [J]. CLINICAL THERAPEUTICS, 1998, 20 (02) : 216 - 231
  • [3] Association of poorly controlled diabetes with low serum leptin in morbid obesity
    Clement, K
    Lahlou, N
    Ruiz, J
    Hager, J
    Bougneres, P
    Basdevant, A
    GuyGrand, B
    Froguel, P
    [J]. INTERNATIONAL JOURNAL OF OBESITY, 1997, 21 (07) : 556 - 561
  • [4] A sib-pair analysis study of 15 candidate genes in French families with morbid obesity -: Indication for linkage with islet 1 locus on chromosome 5q
    Clément, K
    Dina, C
    Basdevant, A
    Chastang, N
    Pelloux, V
    Lahlou, N
    Berlan, M
    Langin, D
    Guy-Grand, B
    Froguel, P
    [J]. DIABETES, 1999, 48 (02) : 398 - 402
  • [5] A Pro12Ala substitution in PPARγ2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity
    Deeb, SS
    Fajas, L
    Nemoto, M
    Pihlajamäki, J
    Mykkänen, L
    Kuusisto, J
    Laakso, M
    Fujimoto, W
    Auwerx, J
    [J]. NATURE GENETICS, 1998, 20 (03) : 284 - 287
  • [6] 15-DEOXY-DELTA(12,14)-PROSTAGLANDIN J(2) IS A LIGAND FOR THE ADIPOCYTE DETERMINATION FACTOR PPAR-GAMMA
    FORMAN, BM
    TONTONOZ, P
    CHEN, J
    BRUN, RP
    SPIEGELMAN, BM
    EVANS, RM
    [J]. CELL, 1995, 83 (05) : 803 - 812
  • [7] A primary prevention trial using nutritional doses of antioxidant vitamins and minerals in cardiovascular diseases and cancers in a general population: The SU.VI.MAX study - Design, methods, and participant characteristics
    Hercberg, S
    Preziosi, P
    Briancon, S
    Galan, P
    Triol, I
    Malvy, D
    Roussel, AM
    Favier, A
    [J]. CONTROLLED CLINICAL TRIALS, 1998, 19 (04): : 336 - 351
  • [8] Peroxisome proliferators and peroxisome proliferator activated receptors (PPARs) as regulators of lipid metabolism
    Latruffe, N
    Vamecq, J
    [J]. BIOCHIMIE, 1997, 79 (2-3) : 81 - 94
  • [9] AN ANTIDIABETIC THIAZOLIDINEDIONE IS A HIGH-AFFINITY LIGAND FOR PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA(PPAR-GAMMA)
    LEHMANN, JM
    MOORE, LB
    SMITHOLIVER, TA
    WILKISON, WO
    WILLSON, TM
    KLIEWER, SA
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (22) : 12953 - 12956
  • [10] Pro12Ala substitution in the peroxisome proliferator-activated receptor-γ2 is not associated with type 2 diabetes
    Mancini, FP
    Vaccaro, O
    Sabatino, L
    Tufano, A
    Rivellese, AA
    Riccardi, G
    Colantuoni, V
    [J]. DIABETES, 1999, 48 (07) : 1466 - 1468